Skip to content

SANGAMO THERAPEUTICS, INC

SGMOQ · OTCM

CIK 1001233fmd_0PA2E3EMHH7T13ZPF8XFE3K3Q7Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard

Coverage: Jan 01, 2009 to Mar 31, 2026, 65 periods

Latest annual · FY2025

Millions
Total revenues
40
Operating income
(121)
Net income
(123)
Free cash flow
(97)

Latest quarter · Q1 FY2026

Millions
Total revenues
1
Operating income
(32)
Net income
(31)
Free cash flow
(19)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2022 to FY2025
-29.2%
Revenue, 5 yearsFY2020 to FY2025
-19.7%
Net income, 5 yearsFY2020 to FY2025
n/m

SANGAMO THERAPEUTICS, INC (SGMOQ) financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2025FY2024ChangeSource
Revenue$39.6 million$57.8 million-31.6%10-K 2026-03-30 · proof
Operating income-$121.2 million-$104 million10-K 2026-03-30 · proof
Net income-$122.9 million-$97.9 million10-K 2026-03-30 · proof
Cash from operating activities-$97.2 million-$67.1 million10-K 2026-03-30 · proof
Free cash flow-$97.3 million-$67.4 million10-K 2026-03-30 · proof
Total assets$59.7 million$101.6 million-41.2%10-K 2026-03-30 · proof
Total liabilities$74 million$78.9 million-6.2%10-K 2026-03-30 · proof
Cash and cash equivalents$20.9 million$41.9 million-50%10-K 2026-03-30 · proof
What was SANGAMO THERAPEUTICS, INC (SGMOQ)'s revenue in fiscal 2025?
SANGAMO THERAPEUTICS, INC (SGMOQ) reported revenue of $39.6 million for fiscal 2025 (the year ended Dec 31, 2025), against $57.8 million the year before (-31.6%). Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
What was SANGAMO THERAPEUTICS, INC (SGMOQ)'s operating income in fiscal 2025?
SANGAMO THERAPEUTICS, INC (SGMOQ) reported operating income of -$121.2 million for fiscal 2025 (the year ended Dec 31, 2025), against -$104 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
What was SANGAMO THERAPEUTICS, INC (SGMOQ)'s net income in fiscal 2025?
SANGAMO THERAPEUTICS, INC (SGMOQ) reported net income of -$122.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$97.9 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
What was SANGAMO THERAPEUTICS, INC (SGMOQ)'s cash from operating activities in fiscal 2025?
SANGAMO THERAPEUTICS, INC (SGMOQ) reported cash from operating activities of -$97.2 million for fiscal 2025 (the year ended Dec 31, 2025), against -$67.1 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
What was SANGAMO THERAPEUTICS, INC (SGMOQ)'s free cash flow in fiscal 2025?
SANGAMO THERAPEUTICS, INC (SGMOQ) reported free cash flow of -$97.3 million for fiscal 2025 (the year ended Dec 31, 2025), against -$67.4 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
What are SANGAMO THERAPEUTICS, INC (SGMOQ)'s total assets?
As of Dec 31, 2025, SANGAMO THERAPEUTICS, INC (SGMOQ) reported total assets of $59.7 million, against $101.6 million a year earlier (-41.2%). Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
What are SANGAMO THERAPEUTICS, INC (SGMOQ)'s total liabilities?
As of Dec 31, 2025, SANGAMO THERAPEUTICS, INC (SGMOQ) reported total liabilities of $74 million, against $78.9 million a year earlier (-6.2%). Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
What are SANGAMO THERAPEUTICS, INC (SGMOQ)'s cash and cash equivalents?
As of Dec 31, 2025, SANGAMO THERAPEUTICS, INC (SGMOQ) reported cash and cash equivalents of $20.9 million, against $41.9 million a year earlier (-50%). Source: the 10-K filed with the SEC on Mar 30, 2026. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:SGMOQ&period_type=annual&limit=5"

Information only, not investment advice.